Psilocybin-containing tea bag offers
substitute for whole mushrooms and other solid therapeutics
VANCOUVER, B.C, Oct. 5, 2022
/CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company")
(TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing
innovative treatments and safe, evidence-based psychedelic-assisted
therapies, today announced that its research division, Numinus
Bioscience, has developed a psilocybin-containing tea bag for use
in clinical research and, if appropriate regulatory approvals are
granted, eventual treatment of clients in psychedelic-assisted
therapy.
"The Numinus team has developed the Psilocybe tea bag
with scientific precision in mind," said Sharan Sidhu, Numinus VP, Scientific Research,
Innovation & Laboratory Operations. "Our best-in-class team and
resources allow us to control the full production process, from
growth to finished product manufacturing, to deliver a product that
is fully standardized."
The research behind the tea bag involved the development of
processes and procedures to deliver 25mg per dose and the use of
Numinus' validated strains of Psilocybe cubensis. The tea
bag will be studied in a phase 1 trial of practitioners receiving
experiential training for psilocybin-assisted therapy, with the
goal to be used in Numinus' research, including trial partnerships
at Cedar Clinical Research, Numinus' clinical trial management
division. The product has also been submitted to Health Canada to
be included on the psilocybin supplier list for the federal Special
Access Program, through which health care providers can apply to
provide psilocybin-assisted therapy, among other
psychedelic-assisted therapies, to patients with demonstrable
need.
"Numinus recognizes that solid therapeutic products, such as
whole mushrooms or pills, might be unappealing or difficult to use
by certain populations, such as some people receiving palliative
care for serious illnesses," said Dr. Paul
Thielking, Numinus Chief Science Officer. "This new product
is part of our commitment to increasing accessibility to
psychedelic-assisted therapies for those in need, while
contributing to the growing research that suggests psilocybin use
in combination with therapy may be highly effective for treating
mental health disorders."
About Numinus
Numinus Wellness (TSX: NUMI) helps people to heal and be well
through the development and delivery of innovative mental health
care and access to safe, evidence-based psychedelic-assisted
therapies. The Numinus model - including psychedelic production,
research and clinic care - is at the forefront of a transformation
aimed at healing rather than managing symptoms for depression,
anxiety, trauma, pain and substance use. At Numinus, we are leading
the integration of psychedelic-assisted therapies into mainstream
clinical practice and building the foundation for a healthier
society.
Learn more at numinus.com and follow us
on LinkedIn, Facebook, Twitter,
and Instagram.
Disclaimer
Neither Numinus Wellness Inc., nor any of its subsidiaries is
a professional corporation licensed to practice health services. In
jurisdictions where health services may only be provided by a
corporation if that corporation holds a valid permit to do so,
Numinus and its subsidiaries operate in a management services
function to affiliated professional corporations, who provide
health services to patients. Numinus and its subsidiaries do
provide health services directly to patients in those jurisdictions
where authorized to do so.
Forward-looking
statements
This press release contains forward-looking statements within
the meaning of applicable securities laws. All statements that are
not historical facts, including without limitation, statements
regarding future estimates, plans, programs, forecasts,
projections, objectives, assumptions, expectations or beliefs
regarding future performance are "forward-looking statements".
Forward-looking statements can be identified by the use of words
such as "expects", "does not expect", "is expected", "believes",
"intends", "anticipates", "does not anticipate", "believes" or
variations of these words, expressions or statements, that certain
actions, events or results "may", "could", "would", "might" or
"will be" taken, will occur or will be realized. Such
forward-looking statements involve risks, uncertainties and other
known and unknown factors that could cause actual results, events
or developments to differ materially from the results, events or
developments expected and expressed or implied in such
forward-looking statements. These risks and uncertainties include,
but are not limited to, dependence on obtaining and maintaining
regulatory approvals, including the acquisition and renewal of
federal, provincial, state, municipal, local or other licenses, and
any inability to obtain all necessary government authorizations,
licenses and permits to operate and expand the Company's
facilities; regulatory or policy changes such as changes in
applicable laws and regulations, including federal, state and
provincial legalization, due to fluctuations in public opinion,
industry perception of integrative mental health, including the use
of psychedelic-assisted therapy, delays or inefficiencies or any
other reason; any other factor or development likely to hamper the
growth of the market; the Company's limited operating and
profitability track record; dependence on management; the Company's
need for additional financing and the effects of financial market
conditions and other factors on the availability of capital;
competition, including that of more established and better funded
competitors; the impact of the Russia-Ukraine conflict on the global economy; the
continued impact of the COVID-19 pandemic; and the need to build
and maintain alliances and partnerships, including with research
and development companies, customers and suppliers. These factors
should be carefully considered, and readers are cautioned not to
place undue reliance on forward-looking statements. Despite the
Company's efforts to identify the main risk factors that could
cause actual measures, events or results to differ materially from
those described in forward-looking statements, other risk factors
may cause measures, events or developments to materially differ
from those anticipated, estimated or intended. There can be no
assurance that forward-looking statements will prove to be
accurate, as actual results and future events could differ
materially from those anticipated in forward-looking statements.
The Company does not undertake to revise forward-looking
statements, even if new information becomes available as a result
of future events, new facts or any other reason, except as required
by applicable laws.
View original
content:https://www.prnewswire.com/news-releases/numinus-develops-mushroom-tea-for-use-in-psychedelic-research-301641145.html
SOURCE Numinus Wellness Inc.
